Biotech - Alpha Briefing

Alpha Briefing

Sign in Subscribe

Biotech

A collection of 14 posts

$TWST: Twist Bioscience Is Up 566% and Now Trades Above Wall Street's Raised Target. It All Rides on November 13.

Paid-members only

Ticker Lane Featured

$TWST: Twist Bioscience Is Up 566% and Now Trades Above Wall Street's Raised Target. It All Rides on November 13.

Twist Bioscience surged 16% to lead the market on an Eli Lilly TuneLab AI deal and a Leerink upgrade, capping a 566% year. At 27x sales and above the bulls' raised target, the November 13 breakeven report is the first hard test.

$ATYR: The FDA Just Cleared aTyr's Second Shot. The Market Values the Company at Less Than Its Bank Account.

Paid-members only

Ticker Lane Featured

$ATYR: The FDA Just Cleared aTyr's Second Shot. The Market Values the Company at Less Than Its Bank Account.

aTyr Pharma got FDA alignment on a new Phase 3 for efzofitimod a year after an 83% one-day collapse. At $0.37, below net cash, the next sixty days decide the trade, not the science: a reverse-split vote and a Nasdaq deadline.

Merck's New Cholesterol Pill Is a Bet on a Drug Class That Already Failed Twice

Healthcare Featured

Merck's New Cholesterol Pill Is a Bet on a Drug Class That Already Failed Twice

The FDA just cleared the first cholesterol-lowering pill as powerful as the injectable drugs that flopped a decade ago. Merck needs it to help fill a $30 billion hole — and the math is harder than the headlines suggest.

Outlook Therapeutics (OTLK) Faces a Binary FDA Verdict on July 29 — With a Reverse-Split-and-Dilution Vote Stacked in Front of It

Paid-members only

Finance Featured

Outlook Therapeutics (OTLK) Faces a Binary FDA Verdict on July 29 — With a Reverse-Split-and-Dilution Vote Stacked in Front of It

OTLK faces a binary July 29 FDA verdict on the first approved ophthalmic bevacizumab for wet AMD after a senior FDA body overruled three rejections — but its confirmatory trial missed its primary endpoint, and a reverse-split-and-dilution vote lands the next day.

OTLK: Twenty-Six Days to the FDA Decision — and the Price-Target Math Nobody Is Doing

Paid-members only

Healthcare Featured

OTLK: Twenty-Six Days to the FDA Decision — and the Price-Target Math Nobody Is Doing

The FDA decides on LYTENAVA July 29. Consensus says $5.50; Ascendiant says $10; the stock says $1.45. The gap isn't about the drug — it's about a share count most quote screens have wrong, a July 16 shareholder vote, and a launch warning already visible in Europe. Our scenario-by-scenario framework.

The World's Richest Men Are Funding a War on Aging

Healthcare Featured

The World's Richest Men Are Funding a War on Aging

Billionaires and a Saudi sovereign fund are pouring capital into treating aging as a disease. The science finally turned a corner — but the FDA still refuses to call aging one, and that single definition is the whole trade.

Outlook Therapeutics Has Sixty Days. Then Everything Changes.

Healthcare Featured

Outlook Therapeutics Has Sixty Days. Then Everything Changes.

The FDA already conceded that LYTENAVA works. Now Outlook Therapeutics has roughly 60 days for a Class 1 resubmission decision — and a $100 million stock sitting on top of a multi-billion-dollar wet AMD market. Here is the actual setup, the three launch scenarios, and how to think about positioning.

👁️ Outlook Therapeutics Eyes FDA Approval of Wet AMD Drug as Investors Bet on Upside

Biotech Featured

👁️ Outlook Therapeutics Eyes FDA Approval of Wet AMD Drug as Investors Bet on Upside

Outlook Therapeutics ($OTLK) is approaching a critical FDA decision this month for its wet AMD drug Lytenava. Approval could unlock a large market and reprice the stock sharply higher, while failure keeps risk elevated. This is a highstakes biotech moment investors are watching closely.

🧠 Quantum Sensors Inside Living Cells: The Next Frontier for Brain-Computer Interfaces

Paid-members only

Frontier Tech Featured

🧠 Quantum Sensors Inside Living Cells: The Next Frontier for Brain-Computer Interfaces

Quantum sensors grown in living cells could transform brain-computer interfaces within a decade. From Medtronic to Meta, here are the stocks best positioned to profit as quantum biology moves from lab to market.

👁️ 👁️ OTLK’s FDA Catalyst: Inside the High-Stakes Biotech Play That Could Redefine Retinal Therapy

Paid-members only

Premium Briefing Featured

👁️ 👁️ OTLK’s FDA Catalyst: Inside the High-Stakes Biotech Play That Could Redefine Retinal Therapy

OTLK is days away from an FDA ruling that could transform retinal care. Already approved in Europe, its U.S. fate on Aug 27 may unlock a multibillion-dollar market. History shows biotechs can swing hundreds of percent into decisions—this setup could be one of 2025’s biggest catalysts.

🧬 Biotech and Battlespace: DARPA’s Quiet Race to Weaponize Genetics

Paid-members only

Biotech Featured

🧬 Biotech and Battlespace: DARPA’s Quiet Race to Weaponize Genetics

📈 Rally or Reversal? Your Weekly Operational Brief (July 7–11, 2025)

Paid-members only

Premium Briefing Featured

📈 Rally or Reversal? Your Weekly Operational Brief (July 7–11, 2025)

🧬 The Biotech Rebellion: 7 Stocks Leading the Next Medical Revolution

Paid-members only

Premium Briefing Featured

🧬 The Biotech Rebellion: 7 Stocks Leading the Next Medical Revolution

🧬 OTLK: Outlook Therapeutics Poised for a Defining FDA Decision in 2025

Paid-members only

Biotech Featured

🧬 OTLK: Outlook Therapeutics Poised for a Defining FDA Decision in 2025

Operated by veterans. Driven by discipline. Built for the early mover.
AlphaBriefing provides financial commentary and market analysis for informational purposes only. We do not offer personalized investment advice. All content is opinion-based and should not be considered a recommendation to buy or sell any security. Past performance is not indicative of future results. Investing involves risk, including the potential loss of principal. Individual results may vary. We value your privacy. Any data collected is used to improve your experience and to provide relevant updates about our services.
©2025 AlphaBriefing. All rights reserved. | Privacy Policy | Legal Disclaimer